First patient implanted with Sequana Medical's pump to remove excess
27 November 2014
Zurich-based Sequana Medical AG has announced that the first
patient has been implanted with its pump to remove excess fluid
around the lungs.
A patient at Hôpital Nord, Marseille, France, was implanted
with the company's pleurapump system designed to manage chronic
pleural effusions in patients with conditions such as congestive
heart failure, pneumonia, or liver disease.
The patient is the first to be enrolled in the Company’s ADEPT
study, which will assess the feasibility of this new therapy for
management of pleural effusions.
The pleurapump system is a fully implantable battery-powered pump
system that automatically and continually moves chronic pleural
effusions from the pleural space around the lungs to the bladder,
where it is passed naturally from the body. The system is designed
to manage fluid balance within the body which helps patients live
more independently, improves patient quality of life and reduces
health care costs.
The most common causes of pleural effusions are congestive heart
failure, pneumonia, liver disease, end-stage renal disease and
cancer. Symptoms include shortness of breath, chest pain, fever and
cough. Pleural effusions are managed with medication in most cases,
but with certain cancers, chronic effusions are difficult to
Current treatments include drainage of fluid using in-dwelling
catheters or pleurodesis, a sometimes painful procedure in which the
membranes around the lungs are fused together, preventing further
accumulation of fluid but leading to a few days of hospitalisation.
It is estimated that more than 300,000 patients are affected by
malignant pleural effusions in the US and Europe each year.
Doctors are excited about this potential new treatment option.
Prof. Philippe Astoul, Head of the Department of Thoracic Oncology,
Pleural Disease and Interventional Pneumology at Hôpital Nord,
Marseille, and Dr Sophie Laroumagne, investigators in the ADEPT
study said: "Use of the pleurapump system in patients with
malignancy-related pleural effusions looks very promising, and could
help patients improve their quality of life at a very challenging
stage of their disease progression. We are delighted that Hôpital
Nord is leading the way in making this solution available to many
thousands of patients in the future.
"Our patient has now had the pump for over a month, is doing very
well, and has reported an improvement in quality of life and high
level of satisfaction with the pump system. The system is very
promising and we are looking forward to the completion of the
Sequana Medical’s CEO, Noel L. Johnson said, "I am delighted that
the ADEPT study is underway, and that patients affected with pleural
effusions will soon be able to benefit from Sequana Medical’s
innovative technology for the management of fluid within the body.
Sequana Medical’s first product, the alfapump system, was developed
for the management of refractory ascites in cirrhotic patients.
Since its introduction in 2012, this pioneering therapy has
demonstrated improved clinical outcomes, reduced the cost of
healthcare and helped hundreds of patients improve their quality of
Source: Sequana Medical